1
|
Boisson M, Torres BGS, Yani S, Couet W, Mimoz O, Dahyot-Fizelier C, Marchand S, Grégoire N. Reassessing the dosing of cefoxitin prophylaxis during major abdominal surgery: insights from microdialysis and population pharmacokinetic modelling. J Antimicrob Chemother 2019; 74:1975-1983. [DOI: 10.1093/jac/dkz139] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Revised: 03/04/2019] [Accepted: 03/07/2019] [Indexed: 11/13/2022] Open
Abstract
Abstract
Objectives
Cefoxitin is frequently used for surgical antibiotic prophylaxis (SAP). Using microdialysis, we evaluated whether the currently recommended dosing regimen is appropriate to maintain cefoxitin subcutaneous tissue concentrations above the MIC for pathogens involved in abdominal surgical site infection.
Methods
Data from eight patients undergoing major abdominal surgery were analysed using population pharmacokinetic modelling, and Monte Carlo simulations were conducted to determine the PTA for aerobic and anaerobic pathogens. ClinicalTrials.gov: NCT02703857.
Results
Only 2.3% and 47.4% of the simulated patients maintained cefoxitin subcutaneous concentrations above the MIC breakpoint for anaerobic (MIC = 16 mg/L) and aerobic (MIC = 8 mg/L) pathogens, respectively. New simulations with administration of a loading dose followed by a constant infusion of cefoxitin were conducted and demonstrate that, notwithstanding using the same total dose per unit of time, continuous infusion of cefoxitin can cover aerobes in 96.6% of the simulated patients, but remains insufficient for anaerobic bacteria.
Conclusions
The recommended dosing regimen of cefoxitin is insufficient for covering the usual bacteria during abdominal surgery. Administration of a loading dose followed by a constant infusion should be considered for aerobic bacteria and cefoxitin should be avoided as SAP for anaerobic bacteria.
Collapse
Affiliation(s)
- Matthieu Boisson
- Inserm U1070, Pôle Biologie Santé, 1 rue Georges Bonnet, Poitiers, France
- Université de Poitiers, UFR Médecine-Pharmacie, 6 rue de la milétrie, Poitiers, France
- Département d’Anesthésie-Réanimation, CHU de Poitiers, 2 rue de la milétrie, Poitiers, France
| | - Bruna Gaelzer Silva Torres
- Inserm U1070, Pôle Biologie Santé, 1 rue Georges Bonnet, Poitiers, France
- Université de Poitiers, UFR Médecine-Pharmacie, 6 rue de la milétrie, Poitiers, France
| | - Sabrina Yani
- Département d’Anesthésie-Réanimation, CHU de Poitiers, 2 rue de la milétrie, Poitiers, France
| | - William Couet
- Inserm U1070, Pôle Biologie Santé, 1 rue Georges Bonnet, Poitiers, France
- Université de Poitiers, UFR Médecine-Pharmacie, 6 rue de la milétrie, Poitiers, France
- Service de Toxicologie-Pharmacocinétique, CHU de Poitiers, 2 rue de la milétrie, Poitiers, France
| | - Olivier Mimoz
- Inserm U1070, Pôle Biologie Santé, 1 rue Georges Bonnet, Poitiers, France
- Université de Poitiers, UFR Médecine-Pharmacie, 6 rue de la milétrie, Poitiers, France
- Service des Urgences & SAMU 86 - Centre 15, CHU de Poitiers, 2 rue de la milétrie, Poitiers, France
| | - Claire Dahyot-Fizelier
- Inserm U1070, Pôle Biologie Santé, 1 rue Georges Bonnet, Poitiers, France
- Université de Poitiers, UFR Médecine-Pharmacie, 6 rue de la milétrie, Poitiers, France
- Département d’Anesthésie-Réanimation, CHU de Poitiers, 2 rue de la milétrie, Poitiers, France
| | - Sandrine Marchand
- Inserm U1070, Pôle Biologie Santé, 1 rue Georges Bonnet, Poitiers, France
- Université de Poitiers, UFR Médecine-Pharmacie, 6 rue de la milétrie, Poitiers, France
- Service de Toxicologie-Pharmacocinétique, CHU de Poitiers, 2 rue de la milétrie, Poitiers, France
| | - Nicolas Grégoire
- Inserm U1070, Pôle Biologie Santé, 1 rue Georges Bonnet, Poitiers, France
- Université de Poitiers, UFR Médecine-Pharmacie, 6 rue de la milétrie, Poitiers, France
- Service de Toxicologie-Pharmacocinétique, CHU de Poitiers, 2 rue de la milétrie, Poitiers, France
| |
Collapse
|
2
|
Yoshizato K, Tateno C. In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 2010; 5:1435-46. [PMID: 19715443 DOI: 10.1517/17425250903216664] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The liver occupies a central place in the treatment of the substances taken into the body. If we could devise an in vivo or in vitro model that perfectly mimics the naturally-created human (h) liver, the work required for making effective and safe medicines would become easier and could be undertaken more cost effectively than it is currently. Considering the advantages of in vivo modeling over in vitro modeling under the current technological state of life sciences research, we have created an experimentally workable in vivo h-liver model, a liver-humanized mouse, in which host hepatocytes are largely replaced with healthy normal h-hepatocytes. Xenogenic h-hepatocytes are capable of constructing a histologically normal liver by collaborating with mouse-nonparenchymal cells in an elaborately organized manner. Considering its potential use for drug development, we have extensively characterized the mouse regarding the infectivity toward h-hepatitis viruses, activities of h-enzymes in Phase I and II of drug metabolisms, and h-hepatocyte-related drug transporters. These studies indicate that the humanized mouse liver mimics h-phenotypes at a level appropriate for pharmacological studies, and, thus, can be used not only for developing new medicines, but also for examining biological and pathological mechanisms in the h-liver.
Collapse
|
3
|
Yoshizato K, Tateno C. A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans. PPAR Res 2009; 2009:476217. [PMID: 19884982 PMCID: PMC2768028 DOI: 10.1155/2009/476217] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2009] [Accepted: 07/13/2009] [Indexed: 01/16/2023] Open
Abstract
Preclinical studies to predict the efficacy and safety of drugs have conventionally been conducted almost exclusively in mice and rats as rodents, despite the differences in drug metabolism between humans and rodents. Furthermore, human (h) viruses such as hepatitis viruses do not infect the rodent liver. A mouse bearing a liver in which the hepatocytes have been largely repopulated with h-hepatocytes would overcome some of these disadvantages. We have established a practical, efficient, and large-scale production system for such mice. Accumulated evidence has demonstrated that these hepatocyte-humanized mice are a useful and reliable animal model, exhibiting h-type responses in a series of in vivo drug processing (adsorption, distribution, metabolism, excretion) experiments and in the infection and propagation of hepatic viruses. In this review, we present the current status of studies on chimeric mice and describe their usefulness in the study of peroxisome proliferator-activated receptors.
Collapse
|
4
|
Katoh M, Tateno C, Yoshizato K, Yokoi T. Chimeric mice with humanized liver. Toxicology 2007; 246:9-17. [PMID: 18248870 DOI: 10.1016/j.tox.2007.11.012] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2007] [Revised: 11/09/2007] [Accepted: 11/12/2007] [Indexed: 02/06/2023]
Abstract
Recently, chimeric mice with humanized liver were established by transplanting human hepatocytes into an urokinase-type plasminogen activator(+/+)/severe combined immunodeficient transgenic mouse line. The replacement with human hepatocytes is more than 80-90% and is higher than any other chimeric mouse reported previously. In drug development, the liver is one of the most important organs because it is mainly involved in the pharmacokinetics of drugs and is frequently damaged by many drugs due to the accumulation of drugs and/or metabolites. The pharmacokinetics could affect the efficacy and toxicity of a drug, and thus prediction of the human pharmacokinetics is important for developing new drugs without adverse reactions and toxicity. Extrapolation from experimental animals or in vitro studies to the human in vivo pharmacokinetics is still difficult. To date, human hepatocytes and liver microsomes are recognized as better tools and are frequently used to estimate the human pharmacokinetics. We thought that chimeric mice with humanized liver could become a new tool for estimating the human toxicity and pharmacokinetics. At first, metabolism, which plays an essential role in pharmacokinetics, was investigated in the chimeric mice. In the liver of the chimeric mice, human drug metabolizing enzymes were found to be expressed and to reflect the capacities and genetic polymorphism of the donor. In an in vivo study on metabolism, human specific metabolites could be detected in the serum of the chimeric mice indicating that the chimeric mice could be used as an in vivo model to address human metabolism. These results suggested that the chimeric mice could overcome the species differences in drug metabolism and be used to evaluate drug toxicity due to genetic polymorphism. The reasons for drug interaction are often enzyme induction and inhibition. By the treatment with a typical inducer of cytochrome P450 (P450), which is the central drug-metabolizing enzyme, P450s expressed in the liver of the chimeric mice were found to possess induction potencies. After the treatment with a specific inhibitor of human P450, the area under the curve of the P450 metabolite was significantly decreased in the chimeric mice but not in the control mice. Therefore, it was indicated that the chimeric mice could be useful for assessing drug interactions in vivo. Moreover, drug excretion was determined to be humanized because cefmetazole was mainly excreted in urine both in the chimeric mice and humans but in the feces in control uPA(-/-)/SCID mice. Drug transporters expressed in the liver of the chimeric mice were also humanized. In this review, studies of the chimeric mice with humanized liver, particularly on metabolism and excretion, are summarized and the possibility of using the chimeric mice is proposed for the advanced prediction of human pharmacokinetics and toxicity.
Collapse
Affiliation(s)
- Miki Katoh
- Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
| | | | | | | |
Collapse
|
5
|
Abstract
Much effort to extrapolate the in vivo pharmacokinetics of drugs in human from experimental animals or in vitro studies has been made by many researchers. A urokinase-type plasminogen activator+/+/severe combined immunodeficient transgenic mouse line, in which the liver could be replaced by more than 80% with human hepatocytes, was established recently in Japan. This chimeric mouse line is remarkable because the replacement is higher than any other chimeric mouse reported previously. Since the liver is the critical organ involved in the pharmacokinetics of drugs, human liver is essential for the development of new drugs. To predict the human drug metabolism and pharmacokinetics, human hepatocytes and liver microsomes are recognized as better tools and are frequently used. Thus, chimeric mice with humanized liver would have great advantages in studies on drug metabolism and pharmacokinetics. We have evaluated chimeric mice for studies on absorption, distribution, metabolism, and excretion (ADME). In the liver of the chimeric mice, human phase I and phase II enzymes were clarified to be expressed and to have a similar drug metabolizing capacity as the donor. Human specific metabolites could be detected in the serum, suggesting that the chimeric mice might be used as a human ADME model for both in vitro and in vivo studies. For predicting human drug interactions, enzyme induction and inhibition are serious problems. By the treatment with typical inducers, human CYP1A2 and CYP3A4 expressed in the liver of the chimeric mice had induction potencies. After the treatment with quinidine, a specific inhibitor of human CYP2D6, the area under the curve (AUC) of a CYP2D6 metabolite, 4'-hydroxydebrisoquin, was significantly decreased in the chimeric mice but not in the control mice. Therefore, it was indicated that the chimeric mice could be used for assessing the drug interactions via enzyme induction and inhibition. As well as drug metabolism, the drug excretion was demonstrated to be humanized because cefmetazole was mainly excreted in urine both in the chimeric mice and human but in feces in control uPA-/-/SCID mice. In this review, basic researches on ADME in the chimeric mice with humanized liver are summarized and the application of the chimeric mice for predictive ADME is proposed.
Collapse
Affiliation(s)
- Miki Katoh
- Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Japan
| | | |
Collapse
|
6
|
St Peter WL, Redic-Kill KA, Halstenson CE. Clinical pharmacokinetics of antibiotics in patients with impaired renal function. Clin Pharmacokinet 1992; 22:169-210. [PMID: 1559311 DOI: 10.2165/00003088-199222030-00002] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Many antibiotics are eliminated renally and dosage adjustments are commonly made in patients with renal insufficiency. This is a critical review of antibiotic pharmacokinetics in patients with various degrees of renal function. Detailed information regarding pharmacokinetic alterations with specific antibiotics or antibiotic classes has been compiled and tabulated. From pharmacokinetic evidence, recommendations for dosage adjustments of antibiotics are supplied. The criteria used for assigning rating levels to specific pharmacokinetic articles as well as the grading system for dosage adjustments are outlined. In addition, a basic review of pharmacokinetic alterations in renal failure and factors affecting the removal of drugs by haemodialysis is included.
Collapse
Affiliation(s)
- W L St Peter
- Drug Evaluation Unit, Hennepin County Medical Center, Minneapolis, Minnesota
| | | | | |
Collapse
|
7
|
Fillastre JP, Singlas E. Pharmacokinetics of newer drugs in patients with renal impairment (Part I). Clin Pharmacokinet 1991; 20:293-310. [PMID: 2036748 DOI: 10.2165/00003088-199120040-00004] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Many drugs are eliminated via the renal route and the usual dose must be modified in patients with severe renal impairment. This review is an attempt to supply physicians with the more recent data on pharmacokinetic studies of new drugs administered in uraemic patients. The review is in 2 parts: the first indicates the results of studies on the pharmacokinetics of antibiotic agents, antifungal, antiviral and antiulcer drugs, and nonsteroidal anti-inflammatory drugs. Special mention is made of epoetin (recombinant human erythropoietin). It was not possible to give all the information collected from the recent literature: since mild renal failure has little effect on the fate of a drug, pharmacokinetic data obtained in patients with a creatinine clearance (CLCR) of more than 50 ml/min has been omitted. Both the text and tables give recommendations for treating patients with moderate renal insufficiency (CLCR of about 50 ml/min), more severe renal impairment (CLCR between 10 and 50 ml/min) and end-stage renal failure with a very low creatinine clearance (below 10 ml/min). It was not possible to give uniform recommendations (i.e. reducing the dose while maintaining the same interval, or giving the same dose and prolonging the interval). This article follows the recommendations of the authors, which may vary for drugs in similar classes.
Collapse
Affiliation(s)
- J P Fillastre
- Department of Nephrology, School of Medicine, Rouen, France
| | | |
Collapse
|